Charnwood Discovery, part of Concept Life Sciences’ Post

We recently shared our work on using JESS automated western blotting to track phospho-proteins in a signaling pathway. By leveraging biomarkers, we developed a screening cascade that identified drug compounds with high specificity and potency, crucial for advancing therapies with minimal side effects. This approach ensured the targeted inhibition of a signaling pathway branch, offering a more refined and effective therapeutic option. Our findings pave the way for successful transitions from in vitro to in vivo studies, reinforcing the drug development pipeline. Read the full case study here: https://lnkd.in/ew3HpCuu #Biomarkers #DrugDiscovery #westernblotting

Poster presentation not to be missed today at #ENA2024. "Quantification of PI3K/AKT/mTOR pathway inhibition is predictive of biological response” Date: Thursday, October 24   Session title: Biomarkers Assays Poster#: PB196 By using InnoSIGN Comprehensive Pathway Analysis (CPA) it is possible to quantitatively measure the capacity of drugs to inhibit activity of the pathways (like PI3K) and to correlate its activity directly to biological response. Pathway activity measurement is more predictive for the cell growth inhibition than measurement of Ki-67 mRNA expression. The mechanism of action of drugs, including the efficacy on pathway inhibition, can be explored in more detail using CPA and might be used for optimal compound selection and patient stratification. #PI3K #AKT #mTOR #ki67 #CPA

Are you aware of the recent failures of ALS drugs in clinical trials? In this blog we provide insights on the recent setbacks, discuss the increasing need for reliable biomarkers and a path forward with iPSC technology. Read the article here: https://lnkd.in/dTZYBDpv Key highlights: - These recent failures underscore a persistent issue in ALS research: the gap between preclinical success and clinical efficacy - Incorporating relevant biomarkers, like NfL, into the evaluation process can enhance the predictive power of preclinical models - iPSC technology enables studying the disease in a human context, with key biomarkers, providing more accurate predictions on disease mechanisms and drug responses. #news #ALS #stemcell #drugdiscovery #biomarkers #iPSCtechnology

How many of you include clinically-relevant biomarkers in early drug discovery? In this blog you can learn how that could positively affect the clinical outcomes using ALS as an example of the current landscape. Share your thoughts in the comments #ALS #drugdiscovery #biomarkers

🎯 We can identify novel #biomarkers to track the impact of your proposed new lead molecule, or test known biomarkers to support the translation of your potential therapeutic. 👉Speak to us: https://hubs.li/Q030vRYC0 #DrugDiscovery

GRI Bio, Inc. announced positive preclinical results for their lead program, GRI-0621, targeting Idiopathic Pulmonary Fibrosis (IPF). GRI-0621 is an iNKT cell inhibitor that has shown significant reductions in fibrosis and inflammation in preclinical models. Phase 2a biomarker study data is expected in Q3 2024, with topline results anticipated in Q4 2024. IPF is a challenging condition with limited treatment options, and GRI Bio’s advancements could lead to major improvements in patient outcomes. If you are passionate about contributing to groundbreaking biotech advancements, let's connect. I can help you explore opportunities where your expertise can drive forward innovative treatments. #BiotechCareers #IPF #ClinicalResearch

Each month, we share a step from our exclusive infographic designed to help you successfully navigate early-stage therapeutic antibody production. For our last post in the five-part series, we’re spotlighting our expertise in early-stage developability studies. If you find infographics like this one useful, give our post a like! #infographic #TherapeuticAntibody #AntibodyProductionb #scientificdiscovery #WuXiBiologicsCRO #DrugDevelopment

🤝 We, at Scailyte, are thrilled to announce our research collaboration with Visterra Inc., focused on utilizing AI-driven biomarker discovery to enhance the development of novel therapeutics for autoimmune diseases. 🔍 For more information: https://lnkd.in/dr2xHd4W #AutoimmuneDiseases #SingleCellTechnologies #Research #Innovation #Healthcare

🤔Lost in the maze of #AntibodyProduction methods? Let us simplify your decision-making! With endless project deadlines and complex experimental setups, finding the best antibody production method can be daunting for any researcher. Should you go with hybridoma, phage display, or polyclonal production? ✅ Don’t waste precious time! In just 10 questions and less than 2 minutes, our interactive quiz will guide you to the ideal solution tailored to your project’s needs. Whether you are working on therapeutics, diagnostics, or research, ProteoGenix’s expertise ensures precise and reliable answers to optimize your workflow. 👉 Try the quiz now and let us help you drive your project forward with confidence: https://lnkd.in/ewXtq6Cg #Hybridoma #PhageDisplay #PolyclonalAntibodies

🧬 Antibody therapeutics have been used in groundbreaking treatments for various diseases, enhancing targeted drug delivery and personalized medicine. However, challenges such as replicating nature’s ‘secret sauce’, development times and costs, and the complexity of producing antibodies for global markets persist. Our latest R&D trends report showcases how teams across academia and industry on our partnering platform are navigating these obstacles to create innovations leveraging the power of antibodies. Learn more and download the report here: https://lnkd.in/eb2-_PZz Including research from: Oblique Therapeutics AB (publ.) Cleveland Clinic The Research Foundation for SUNY University of Manchester Innovation Factory Penn Center for Innovation #antibodies #antibodytherapies #openinnovation #researchtrends